Colorectal cancer population screening programs worldwide in 2016: An update
- PMID: 28611516
- PMCID: PMC5449420
- DOI: 10.3748/wjg.v23.i20.3632
Colorectal cancer population screening programs worldwide in 2016: An update
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. The incidence and mortality show wide geographical variations. Screening is recommended to reduce both incidence and mortality. However, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide. We reviewed the literature on national and international screening programs published in PubMed, on web pages, and in clinical guidelines. CRC Screening programs are currently underway in most European countries, Canada, specific regions in North and South America, Asia, and Oceania. The most extensive screening strategies were based on fecal occult blood testing, and more recently, the fecal immunochemical test (FIT). Participation in screening has varied greatly among different programs. The Netherlands showed the highest participation rate (68.2%) and some areas of Canada showed the lowest (16%). Participation rates were highest among women and in programs that used the FIT test. Men exhibited the greatest number of positive results. The FIT test has been the most widely used screening program worldwide. The advent of this test has increased participation rates and the detection of positive results.
Keywords: Colonoscopy; Colorectal cancer; Colorectal cancer screening; Fecal immunochemical test; Fecal occult blood test.
Conflict of interest statement
Conflict-of-interest statement: Authors declare no conflicts of interest for this article.
Similar articles
-
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
-
Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round.BMC Gastroenterol. 2012 Jun 19;12:73. doi: 10.1186/1471-230X-12-73. BMC Gastroenterol. 2012. PMID: 22713100 Free PMC article.
-
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2. BMC Cancer. 2022. PMID: 36503495 Free PMC article.
-
Colorectal cancer screening: 20 years of development and recent progress.World J Gastroenterol. 2014 Apr 14;20(14):3825-34. doi: 10.3748/wjg.v20.i14.3825. World J Gastroenterol. 2014. PMID: 24744575 Free PMC article. Review.
-
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).Gut Liver. 2014 Mar;8(2):117-30. doi: 10.5009/gnl.2014.8.2.117. Epub 2014 Mar 11. Gut Liver. 2014. PMID: 24672652 Free PMC article. Review.
Cited by
-
Chondroitin polymerizing factor promotes development and progression of colorectal cancer via facilitating transcription of VEGFB.J Cell Mol Med. 2024 May;28(10):e18268. doi: 10.1111/jcmm.18268. J Cell Mol Med. 2024. PMID: 38775031 Free PMC article.
-
Exploring shared decision-making needs in lung cancer screening among high-risk groups and health care providers in China: a qualitative study.BMC Cancer. 2024 May 21;24(1):613. doi: 10.1186/s12885-024-12360-0. BMC Cancer. 2024. PMID: 38773461 Free PMC article.
-
Patterns of Care Following a Positive Fecal Blood Test for Colorectal Cancer: A Mixed Methods Study.J Gen Intern Med. 2024 May 21. doi: 10.1007/s11606-024-08764-0. Online ahead of print. J Gen Intern Med. 2024. PMID: 38771535
-
Explorative cost-effectiveness analysis of colorectal cancer recurrence detection with next-generation sequencing liquid biopsy in Spain, France, and Germany.Therap Adv Gastroenterol. 2024 May 10;17:17562848241248246. doi: 10.1177/17562848241248246. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 38737912 Free PMC article.
-
Prevalence of colonoscopy in Japan using a large-scale health claims data compared to esophagogastroduodenoscopy.J Gastroenterol. 2024 Jun;59(6):457-467. doi: 10.1007/s00535-024-02087-x. Epub 2024 Mar 11. J Gastroenterol. 2024. PMID: 38466371
References
-
- Globocan. Estimated cancer incidence, mortality and prevalence worldwide in 2012. (2012) Available from: http://globocan.iarc.fr/Default.aspx.
-
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Ferlay J. Cancer incidence in five continents. Vol X. International Agency for Research on Cancer; 2014. - PubMed
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
-
- Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–1649. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical